Effects of different doses of CSA, RAPA, and MMF on GVHD-related mortality. Data from 3 independent experiments are combined. (A) Percentage survival of animals receiving CSA 10 mg/kg (□, n = 12), CSA 50 mg/kg (▪, n = 12), or PBS (⋄, n = 12). The higher CSA dose improves survival (▪ versus ⋄, P = 0.032). (B) Percentage survival of animals receiving RAPA 0.5 mg/kg (○, n = 12), RAPA 1.5 mg/kg (•, n = 12), or PBS (⋄, n = 12). The higher RAPA dose improves survival (• versus ⋄, P = 0.029). (C) Percentage survival of animals receiving MMF 90 mg/kg (▵, n = 12), MMF 200 mg/kg (▴, n = 12), or PBS (⋄, n = 12), not significant (NS). Control animals received TCD-BM only (^*). (D) Distribution of donor derived luc⁺ T_CONV cells in Balb/c recipients at day 5 after BMT with coadministration of different doses of CSA (top row), RAPA (middle row), and MMFl (bottom row). At this time point the major T_CONV expansion is found in cLNs, GIT, and SPL. Although the localization pattern of T_CONV is conserved, proliferation is gradually reduced when different doses of immunosuppressants are administered.